Related Experiment Videos
Circulating interleukin-16 in systemic lupus erythematosus
1Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Japan.
British Journal of Rheumatology
|February 11, 1999
Summary
Interleukin-16 (IL-16) levels are significantly elevated in patients with systemic lupus erythematosus (SLE). Higher IL-16 correlates with increased SLE disease activity, suggesting it is a useful biomarker.
Area of Science:
- Immunology
- Rheumatology
Background:
- Systemic lupus erythematosus (SLE) is a chronic autoimmune disease.
- The role of specific cytokines in SLE pathogenesis requires further elucidation.
Purpose of the Study:
- To investigate the association between Interleukin-16 (IL-16) and systemic lupus erythematosus (SLE).
- To determine if IL-16 levels correlate with SLE disease activity.
Main Methods:
- Serum IL-16 levels were quantified in SLE patients and healthy controls using enzyme-linked immunosorbent assay (ELISA).
- Disease activity was assessed using the SLE Disease Activity Index (SLEDAI) score.
Main Results:
- Serum IL-16 levels were significantly higher in SLE patients compared to healthy volunteers (P < 0.001).
- A positive correlation was observed between IL-16 levels and SLEDAI scores (P < 0.0001), indicating increased IL-16 with higher disease activity.
Conclusions:
- IL-16 production is linked to disease activity in SLE.
- IL-16 emerges as a potential biomarker for monitoring SLE disease activity.